The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome

Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome

July 14, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

He also discussed some of the newer immunosuppressive approaches to treatment that focus on complement and mechanistic target of rapamycin (mTOR) pathway inhibition.

You Might Also Like
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
  • ACR/ARHP Annual Meeting 2012: Tips to Diagnose and Treat Catastrophic Antiphospholipid Syndrome (CAPS)
Explore This Issue
July 2017
Also By This Author
  • New Insights into the Management of Giant Cell Arteritis

He concluded his talk by briefly discussing the 15th International Congress on Antiphospholipid Antibodies, which met in September 2016. He noted that the abstract booklet is free to download.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Free Resource

For more information on APS, download the free iBook, Antiphospholipid Syndrome. A collaborative project of the Hospital for Special Surgery, N.Y., and Nancy-Lorraine University, Nancy, France, Antiphospholipid Syndrome was developed primarily to help medical students better understand the spectrum of aPL-related clinical problems and receive proper education in the diagnosis and management of APS. The authors are Laurent Phialy, Stéphane Zuily and Doruk Erkan.

References

  1. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014 Sep;13(9):917–930.
  2. Sciascia S, Bertolaccini ML. Thrombotic risk assessment in APS: The Global APS Score (GAPSS). Lupus. 2014;23(12):1286–1287.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Systemic Inflammatory Syndromes Tagged With: 2017 State of the Art Clinical Symposium, AC&R, American College of Rheumatology, Antiphospholipid Antibody Syndrome (APS), Classification Criteria, Diagnosis, Hughes Syndrome, prevention, Research, rheumatology, risk, thrombosis, TreatmentIssue: July 2017

You Might Also Like:
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
  • ACR/ARHP Annual Meeting 2012: Tips to Diagnose and Treat Catastrophic Antiphospholipid Syndrome (CAPS)
  • Antiphospholipid Antibody Syndrome: Much Remains to be Learned

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)